Related Experiment Video

Updated: Oct 10, 2025

Dynamic Digital Biomarkers of Motor and Cognitive Function in Parkinson's Disease
10:28

Dynamic Digital Biomarkers of Motor and Cognitive Function in Parkinson's Disease

Published on: July 24, 2019

15.4K

Predicting the Progression of Parkinson's Disease MDS-UPDRS-III Motor Severity Score from Gait Data using Deep

Rana Zia Ur Rehman, Lynn Rochester, Alison J Yarnall

    Annual International Conference of the IEEE Engineering in Medicine and Biology Society. IEEE Engineering in Medicine and Biology Society. Annual International Conference
    |December 11, 2021
    PubMed

    Abstract:

    Parkinson's disease (PD) is a common neurodegenerative disease presenting with both motor and non-motor symptoms. Among PD motor symptoms, gait impairments are common and evolve over time. PD motor symptoms severity can be evaluated using clinical scales such as the Movement Disorder Society Unified Parkinson's Rating Scale part III (MDS-UPDRS-III), which depend on the patient's status at the time of assessment and are limited by subjectivity. Objective quantification of motor symptoms (i.e. gait) with wearable technology paired with Deep Learning (DL) techniques could help assess motor severity. The aims of this study were to: (i) apply DL techniques to wearable-based gait data to estimate MDS-UPDRS-III scores; (ii) test the DL approach on longitudinal dataset to predict the progression of MDS-UPDRSIII scores. PD gait was measured in the laboratory, during a 2 minute continuous walk, with a sensor positioned on the lower back. A DL Convolutional Neural Network (CNN) was trained on 70 PD subjects (mean disease duration: 3.5 years), validated on 58 subjects (mean disease duration: 5 years) and tested on 46 subjects (mean disease duration: 6.5 years). Model performance was evaluated on longitudinal data by quantifying the association (Pearson correlation (r)), absolute agreement (Intraclass correlation (ICC)) and mean absolute error between the predicted and true MDS-UPDRS-III. Results showed that MDS-UPDRS-III scores predicted with the proposed model, strongly correlated (r=0.82) and had a good agreement (ICC(2,1)=0.76) with true values; the mean absolute error for the predicted MDS-UPDRS-III scores was 6.29 points. The results from this study are encouraging and show that a DL-CNN model trained on baseline wearable-based gait data could be used to assess PD motor severity after 3 years.Clinical Relevance-Gait assessed with wearable technology paired with DL-CNN can estimate PD motor symptom severity and progression to support clinical decision making.

    More Related Videos

    Applying the RatWalker System for Gait Analysis in a Genetic Rat Model of Parkinson's Disease
    04:08

    Applying the RatWalker System for Gait Analysis in a Genetic Rat Model of Parkinson's Disease

    Published on: January 18, 2021

    3.0K
    Behavioral Assessments of Spontaneous Locomotion in a Murine MPTP-induced Parkinson's Disease Model
    05:38

    Behavioral Assessments of Spontaneous Locomotion in a Murine MPTP-induced Parkinson's Disease Model

    Published on: January 7, 2019

    18.3K

    Related Experiment Videos

    Last Updated: Oct 10, 2025

    Dynamic Digital Biomarkers of Motor and Cognitive Function in Parkinson's Disease
    10:28

    Dynamic Digital Biomarkers of Motor and Cognitive Function in Parkinson's Disease

    Published on: July 24, 2019

    15.4K
    Applying the RatWalker System for Gait Analysis in a Genetic Rat Model of Parkinson's Disease
    04:08

    Applying the RatWalker System for Gait Analysis in a Genetic Rat Model of Parkinson's Disease

    Published on: January 18, 2021

    3.0K
    Behavioral Assessments of Spontaneous Locomotion in a Murine MPTP-induced Parkinson's Disease Model
    05:38

    Behavioral Assessments of Spontaneous Locomotion in a Murine MPTP-induced Parkinson's Disease Model

    Published on: January 7, 2019

    18.3K

    Related Concept Videos

    Parkinson's Disease: Overview01:15

    Parkinson's Disease: Overview

    814
    Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
    814

    Articles linked to this work by shared authors, journal, and citation graph.

    Optimising fall risk classification models in Parkinson's disease using clinical and mobility outcomes.

    Parkinsonism & related disorders·2026

    Exploring medication experiences, behaviours, and reminder technology preferences in people with Parkinson's disease: a survey.

    Frontiers in digital health·2026

    Testing the construct validity of real-world digital mobility outcomes in multiple sclerosis.

    Multiple sclerosis (Houndmills, Basingstoke, England)·2026

    Mobgap: A State-of-the-Art Python Framework for Reproducible Estimation and Algorithm Validation of Digital Mobility Outcomes from a Single Wearable Device.

    Sensors (Basel, Switzerland)·2026

    Exploring the feasibility of modeling next-day fatigue and sleepiness using digital sleep tracker data in neurodegenerative and immune-mediated inflammatory diseases.

    Frontiers in digital health·2026

    Use of Wearable Technology for Measuring and Characterizing Sedentary Behavior in People With Mild Cognitive Impairment and Dementia: Systematic Review.

    JMIR aging·2026

    Analysis of End-Tidal CO2 Variability During Plateau Waves Episodes: An Information Theoretic Approach.

    Annual International Conference of the IEEE Engineering in Medicine and Biology Society. IEEE Engineering in Medicine and Biology Society. Annual International Conference·2025

    AI and Tomosynthesis for Breast Cancer Molecular Subtyping: A step toward precision medicine.

    Annual International Conference of the IEEE Engineering in Medicine and Biology Society. IEEE Engineering in Medicine and Biology Society. Annual International Conference·2025

    Towards Sustainable Protein Recovery from Biological Waste: Assessing Polyethersulfone-based Microfiltration.

    Annual International Conference of the IEEE Engineering in Medicine and Biology Society. IEEE Engineering in Medicine and Biology Society. Annual International Conference·2025

    Analysis of the cardiovascular response to standardized polymicrobial peritonitis experimental model.

    Annual International Conference of the IEEE Engineering in Medicine and Biology Society. IEEE Engineering in Medicine and Biology Society. Annual International Conference·2025

    Automated Wrist Ultrasound Image Bone Enhancement and Segmentation Using Deep Learning.

    Annual International Conference of the IEEE Engineering in Medicine and Biology Society. IEEE Engineering in Medicine and Biology Society. Annual International Conference·2025

    A Deep Learning approach for Depressive Symptoms assessment in Parkinson's disease patients using facial videos.

    Annual International Conference of the IEEE Engineering in Medicine and Biology Society. IEEE Engineering in Medicine and Biology Society. Annual International Conference·2025

    Advanced Bisoprolol Oral Liquid Formulations for Flexible Pediatric and Geriatric Pharmacotherapy.

    AAPS PharmSciTech·2026

    Pharmacological and non-pharmacological modulation of striatal dopamine release: a meta-analysis of [11C]raclopride PET studies.

    Molecular psychiatry·2026

    Physicochemical interactions between oral drug products: An integrated in vitro and PBPK modeling approach.

    International journal of pharmaceutics·2026

    Betaine attenuates methamphetamine-induced reinstatement through CAMKK2-AMPK signaling in the nucleus Accumbens Core.

    Progress in neuro-psychopharmacology & biological psychiatry·2026

    Absence of hyperdynamic contractility in the setting of amlodipine-induced shock.

    The American journal of emergency medicine·2026

    Long-term safety and tolerability of lumateperone 42 mg in patients with stable symptoms of schizophrenia: Results from a 1-year open-label study.

    Schizophrenia research·2026
    See all related articles
    JoVE
    x logofacebook logolinkedin logoyoutube logo
    ABOUT JoVE
    OverviewLeadershipBlogJoVE Help Center
    AUTHORS
    Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
    LIBRARIANS
    TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
    RESEARCH
    JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
    EDUCATION
    JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
    Terms & Conditions of Use
    Privacy Policy
    Policies
    Jove
    Visualize
    Contact Us